Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Biodesix Q2 2024 GAAP EPS $(0.08) Beats $(0.09) Estimate, Sales $17.925M Beat $16.214M Estimate

Author: Benzinga Newsdesk | August 07, 2024 04:09pm
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 52.94 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $17.925 million which beat the analyst consensus estimate of $16.214 million by 10.55 percent. This is a 50.99 percent increase over sales of $11.872 million the same period last year.

Posted In: BDSX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist